Correction: The effects of a 6-week intervention with Limosilactobacillus reuteri ATCC PTA 6475 alone and in combination with L. reuteri DSM 17938 on gut barrier function, immune markers, and symptoms in patients with IBS-D—An exploratory RCT
Abstract
Genes, proteins, chemicals, diseases, species, mutations and cell lines named across the full text — each resolved to its canonical identifier and authoritative record.
Peer Reviews
No public reviews on file for this paper yet. If you reviewed it on a platform where reviews are public (OpenReview, ICLR, NeurIPS, ICML), you can paste yours below so the community can read it here.
Videos
No videos yet. Explain this paper in a talk, walkthrough, or lecture? Add one.
Taxonomy
TopicsGut microbiota and health · Gastrointestinal motility and disorders · Probiotics and Fermented Foods
Notice of Republication
This article was republished on December 3, 2024, to address an issue identified post-publication. Please download this article again to view the correct version.
The article’s Data Availability statement is updated to: The data are pseudonymised, meaning that the key variable may not be destroyed. According to Swedish ethics regulations, the raw data cannot be shared without an approved ethics application from the National Swedish Ethics Authority. An ethical permit can only be obtained for research being conducted within Sweden. Data requests can be emailed to [email protected].
The reference list from the paper itself. Each links out to its DOI / PubMed record.
- 1König J, Roca Rubio MF, Forsgård RA, Rode J, Axelsson J, Grompone G, et al. (2024) The effects of a 6-week intervention with Limosilactobacillus reuteri ATCC PTA 6475 alone and in combination with L. reuteri DSM 17938 on gut barrier function, immune markers, and symptoms in patients with IBS-D—An exploratory RCT. P Lo S ONE 19(11): e 0312464. 10.1371/journal.pone.0312464 39485760 PMC 11530048 · doi ↗ · pubmed ↗